Efficacy of Aspirin in the Primary Prevention of Cardiovascular Diseases and Cancer in the Elderly: A Population-Based Cohort Study in Korea
- 58 Downloads
Aspirin is widely used to prevent cardiovascular diseases (CVDs). However, the balance of its benefits and risks in the primary prevention of CVDs and cancer is unclear, especially in elderly Asians. The present study aimed to evaluate the efficacy of aspirin in the primary prevention of major adverse cardiac and cerebrovascular events (MACCE), bleeding risk, and cancer in elderly Koreans with cardiovascular (CV) risk factors.
This retrospective cohort study used data from the Korean National Health Insurance Service–Senior cohort database (2002–2015). Patients aged 60–90 years with hypertension, type 2 diabetes mellitus (T2DM), or dyslipidemia were identified. Aspirin users were compared with non-users using propensity score matching at a 1:3 ratio. The primary outcome was MACCE, a composite of CV mortality, myocardial infarction, and ischemic stroke. The secondary outcomes were the components of MACCE, all-cause mortality, angina pectoris, heart failure, the incidence and mortality of cancer, and the risks of hemorrhagic stroke and gastrointestinal bleeding. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using a Cox proportional hazard model.
A total of 3366 aspirin users and 10,089 non-users were finally included in the study. During a mean follow-up of 7.8 years, the incidence of MACCE was 15.2% in aspirin users and 22.4% in non-users. The risk of MACCE was significantly lower in aspirin users than in non-users (HR 0.76; 95% CI 0.69–0.85), and this risk was significantly reduced in patients using aspirin over 5 years (HR 0.52; 95% CI 0.46–0.60). Aspirin use was associated with a 21% reduction in the risk of primary cancer (HR 0.79; 95% CI 0.70–0.88) and cancer-related mortality (HR 0.72; 95% CI 0.61–0.84). No significant differences in bleeding risks were observed between the two groups.
Aspirin reduced the risks of MACCE and cancer without increasing the bleeding risk in elderly Koreans with hypertension, T2DM, or dyslipidemia. Moreover, the benefits of the long-term use of aspirin in reducing the risks of MACCE were demonstrated. However, the decision of using aspirin for primary prevention must be carefully made on an individual basis, while estimating the benefit–risk balance of aspirin.
Compliance with Ethical Standards
No external funding was used in the conduct of this study.
Conflict of interest
Jung and Lee declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.
- 1.Statistics Korea. Korean Statistical Information Service. 2018. http://kosis.kr/eng/statisticsList/statisticsListIndex.do?menuId=M_01_01&vwcd=MT_ETITLE&parmTabId=M_01_01#SelectStatsBoxDiv. Accessed 04 Jul 2019.
- 11.Rothwell PM, Price JF, Fowkes FGR, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. The Lancet. 2012;379(9826):1602–12.CrossRefGoogle Scholar
- 15.Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–81.PubMedPubMedCentralCrossRefGoogle Scholar
- 16.Arnett DK, Blumenthal RS, Albert MA, Michos ED, Buroker AB, Miedema MD, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. J Am Coll Cardiol. 2019;140:e596–646.Google Scholar
- 19.Sugawara M, Goto Y, Yamazaki T, Teramoto T, Oikawa S, Shimada K, et al. Low-dose aspirin for primary prevention of cardiovascular events in elderly Japanese patients with atherosclerotic risk factors: subanalysis of a randomized clinical trial (JPPP-70). Am J Cardiovasc Drugs. 2019;19(3):299–311.PubMedCrossRefGoogle Scholar
- 21.Lee J, Lee JS, Park S-H, Shin SA, Kim K. Cohort profile: the National Health Insurance Service-National Sample Cohort (NHIS-NSC), South Korea. Int J Epidemiol. 2016;46(2):e15.Google Scholar
- 24.Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285–350.PubMedCrossRefGoogle Scholar
- 25.Linden A, Samuels SJ. Using balance statistics to determine the optimal number of controls in matching studies. J Eval in ClinPract. 2013;19:968–75.Google Scholar
- 26.Teramoto T, Shimada K, Uchiyama S, Sugawara M, Goto Y, Yamada N, et al. Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)—a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events. Am Heart J. 2010;159(3):361–369.e4.PubMedCrossRefGoogle Scholar
- 30.Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. The Lancet. 1998;351(9118):1755–62.CrossRefGoogle Scholar
- 34.Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. The Lancet. 2018;392(10152):1036–46.CrossRefGoogle Scholar
- 40.Elwood PC, Pickering JE, Morgan G, Galante J, Weightman AL, Morris D, et al. Systematic review update of observational studies further supports aspirin role in cancer treatment: time to share evidence and decision-making with patients? PLoS One. 2018;13(9):e0203957.PubMedPubMedCentralCrossRefGoogle Scholar
- 42.Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.PubMedPubMedCentralCrossRefGoogle Scholar
- 44.Elwood PC, Morgan G, Galante J, Chia JW, Dolwani S, Graziano JM, et al. Systematic review and meta-analysis of randomised trials to ascertain fatal gastrointestinal bleeding events attributable to preventive low-dose aspirin: no evidence of increased risk. PLoS One. 2016;11(11):e0166166.PubMedPubMedCentralCrossRefGoogle Scholar
- 45.Huang WY, Saver JL, Wu YL, Lin CJ, Lee M, Ovbiagele B. Frequency of intracranial hemorrhage with low-dose aspirin in individuals without symptomatic cardiovascular disease: a systematic review and meta-analysis. JAMA Neurol. 2019. https://doi.org/10.1001/jamaneurol.2019.1120.CrossRefPubMedGoogle Scholar
- 47.van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. The Lancet Neurol. 2010;9(2):167–76.PubMedCrossRefGoogle Scholar